Previous 10 | Next 10 |
Athersys (NASDAQ: ATHX ) +9% as director Kenneth Traub disclosed stock purchase of 140,000 common stock on June 24. More news on: Athersys, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Puhui Wealth Investment Management (NASDAQ: PHCF ) +70% . More news on: Puhui Wealth Investment Management Co., Ltd., IZEA Worldwide, Inc., Cumulus Media Inc., Stocks on the move, , Read more ...
Gainers: Sintx Technologies (NASDAQ: SINT ) +169% . More news on: Sintx Technologies, Inc., Evoke Pharma, Inc., Ideanomics, Inc., Stocks on the move, , Read more ...
Evoke Pharma (NASDAQ: EVOK ) +85% on FDA approval . More news on: Evoke Pharma, Inc., Theratechnologies Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...
Shares of Athersys (NASDAQ: ATHX) rose over 26% last month, according to data provided by S&P Global Market Intelligence . The stem cell stock's movement in May can primarily be described as a recovery from a lousy April, but two business updates certainly helped. In the first week of ...
The need for medicines that help Covid-19 patients before the disease leaves the viral response phase and enters the host inflammatory phase has never been greater. While there are some positive signals in the prevention area, the most frequent estimates I am reading place a realistic timeli...
Athersys' ( ATHX ) two lead programs in the treatment of ischemic stroke and acute respiratory distress syndrome [ARDS] have to endear it to those who have encountered these miserable afflictions. Each can rise up without notice and punish unwary victims severely. This article reviews Athers...
Company will participate in three events at the largest global translation-focused cell and gene therapy meeting Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year’s International Society for Cell and Gene Therapy (ISCT) virtual co...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q1 2020 Earnings Call May 07, 2020 , 4:30 p.m. ET Operator Continue reading
Athersys, Inc. (ATHX) Q1 2020 Results Earnings Conference Call May 07, 2020, 04:30 PM ET Company Participants Karen Hunady - Director of Corporate Communications and Investor Relations Gil Van Bokkelen - Founder, Chairman and Chief Executive Officer Ivor Macleod - Chief Financial...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...